#biotech

🏢Release 📈 Stocks

Actinium Pharmaceuticals Appoints Industry Veteran to Lead Business Development

October 16, 2026 (25 days ago)

Actinium Pharmaceuticals strengthens its leadership team with a new business development head to drive strategic licensing and commercial growth in the radiopharmaceutical…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Sobi Receives Positive CHMP Opinion for Olezarsen to Treat Triglycerides

October 16, 2026 (25 days ago)

Sobi's TRYNGOLZA receives positive CHMP recommendation following Phase 3 results showing significant reductions in triglyceride levels and acute pancreatitis risk, paving the…

SOBI

🌍 EUROPE Read More →

🏛️Filing 📈 Stocks

ALX Oncology Files 8-K Disclosing Material Agreement and Equity Sale

October 15, 2026 (25 days ago)

ALX Oncology discloses a material definitive agreement and unregistered equity sales in its latest 8-K filing, signaling a strategic capital move.

ALXO

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

New England Biolabs and seqWell Partner to Commercialize TnX Transposase

October 15, 2026 (25 days ago)

New England Biolabs and seqWell join forces to commercialize TnX transposase, aiming to enhance next-generation sequencing library preparation workflows through combined manufacturing…

New England Biolabs seqWell

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Phanes Therapeutics Advances Peluntamig for Neuroendocrine Prostate Cancer

October 15, 2026 (26 days ago)

Phanes Therapeutics accelerates the clinical development of Peluntamig (PT217), targeting the growing demand for specialized therapies in the treatment-resistant neuroendocrine prostate cancer…

PHANES

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Bold Therapeutics Hits 60-Patient Enrollment Milestone in Phase 2 Cancer Trial

October 15, 2026 (26 days ago)

Bold Therapeutics reaches the 60-patient enrollment midpoint in its Phase 2 trial for BOLD-100, advancing its clinical development pipeline for novel metallotherapeutics.

Bold Therapeutics

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Actinium Pharmaceuticals Advances ATNM-400 Prostate Cancer Trial

October 15, 2026 (26 days ago)

Actinium Pharmaceuticals moves forward with its Phase 1 trial for ATNM-400, a novel non-PSMA targeted alpha therapy designed to treat metastatic castration-resistant…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Brii Biosciences Launches BRiSC Platform to Target Metabolic Diseases

October 15, 2026 (26 days ago)

Brii Biosciences introduces its BRiSC siRNA platform to expand its therapeutic pipeline, targeting metabolic diseases through advanced dual-targeting medicine development.

BRII

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Metabolize Secures $3.2 Million Seed Funding to Launch NATLEAN Product Line

October 15, 2026 (26 days ago)

Metabolize secures $3.2 million in seed funding to fuel the January 2027 launch of its NATLEAN product line and scale its proprietary…

METABOLIZE

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Evotec Appoints Dr. Joanna Holbrook as New Chief Scientific Officer

October 15, 2026 (26 days ago)

Evotec SE strengthens its leadership team with the appointment of Dr. Joanna Holbrook as CSO, tasking her with driving differentiation across its…

EVT

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Illumina Launches BioInsight Platform to Accelerate Genomic Data Analysis

October 14, 2026 (27 days ago)

Illumina introduces the BioInsight Platform, featuring AI-driven tools and DRAGEN updates to accelerate genomic analysis and improve research efficiency for multiomic data…

ILMN

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Tempest Therapeutics Appoints John W. Frederick to Board of Directors

October 14, 2026 (27 days ago)

Tempest Therapeutics adds financial veteran John W. Frederick to its board, bolstering the company's leadership team as it advances its clinical-stage CAR-T…

TPST

🌍 US Read More →